荣昌生物早盘涨超13%,月内股价累涨超三成。截至发稿,股价上涨9.60%,报33.10港元,成交额2.28亿港元。近日,荣昌生物宣布其自主研发的BLyS/APRIL双靶点融合蛋白创新药泰它西普(telitacicept,RC18)用于治疗全身型重症肌无力(gMG)3期研究结果。数据显示,泰它西普治疗24周后,98.1%的患者重症肌无力日常活动评分(MG-ADL)改善≥3分,87%的患者定量重症...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.